Leaps by Bayer and other consortium partners

Tracked participation in 1 Atlas company, with 0 explicitly attributed leads.

1portfolio companies

1round participations

0lead positions

Sep 2020latest activity

Capital activity

Portfolio

CompanyLatest valuationFirst → latestRoundsRoleAttributed partner

RRecursionScienceRecursion (NASDAQ: RXRX) is a clinical-stage TechBio company developing an end-to-end, AI-native drug discovery and…$1.2BraisedRecent roundsPublic Offering (equity) · Jun 2024$200M · Public market investors (follow-on offering)PIPE / strategic investment (NVIDIA investment) · Jul 2023$50M · NVIDIADebt financing (credit facility / term loan) · Jan 2023$11.9M · led by Midcap Financial Trust (Midcap)Recursion—Sep 2020 → Sep 20201 roundParticipant—

DateCompanyRoundRaisedValuationRoleEvidence

Sep 09, 2020RRecursionScienceRecursion (NASDAQ: RXRX) is a clinical-stage TechBio company developing an end-to-end, AI-native drug discovery and…$1.2BraisedRecent roundsPublic Offering (equity) · Jun 2024$200M · Public market investors (follow-on offering)PIPE / strategic investment (NVIDIA investment) · Jul 2023$50M · NVIDIADebt financing (credit facility / term loan) · Jan 2023$11.9M · led by Midcap Financial Trust (Midcap)RecursionSeries D (equity financing)$239M—Participant

Source ↗+1 ↗

DateCompanyRoundRaisedValuationRoleEvidence

Source ↗+1 ↗